Mammography Analysis Report

Breast Imaging — Digital Mammography with Tomosynthesis (DBT)

Report ID: MAA-MMG-3D5B22
Generated: May 24, 2026
Analysis: AI-Powered Image Interpretation

Patient Profile

Sex / Age:
Female, 52 years
Indication:
Routine screening, post-menopausal
Symptoms:
None reported. No palpable lump, no nipple discharge, no skin change.
Personal/family history:
No personal history of breast disease. Mother with breast cancer at 65.
Hormone replacement therapy:
None
Study:
Bilateral 4-view digital mammography + tomosynthesis (DBT). Comparison: prior screening 14 months ago.

Summary Overview

Bilateral mammography demonstrates a new, small group of fine pleomorphic microcalcifications in the upper outer quadrant of the right breast, not previously visible. No mass, architectural distortion, or skin/nipple change. Left breast unchanged. BI-RADS 4B (suspicious — moderate probability of malignancy). Diagnostic workup with magnification views and stereotactic biopsy is recommended.

4B
BI-RADS
~10–50%
Malig. Range
B
Density

Categorization & Risk Context

Breast composition:
ACR Density Category B — scattered fibroglandular tissue
Finding:
Grouped pleomorphic microcalcifications, ~5 calcifications in a 6 mm cluster, RUO upper outer quadrant
BI-RADS final assessment:
4B (moderate suspicion; PPV typically 10–50%) [Sickles EA, ACR BI-RADS Atlas 2013]
Comparison:
Calcifications were not present on prior study 14 months ago — interval change increases suspicion

Detailed Imaging Findings

Right Breast — Upper Outer QuadrantSuspicious
Approximately 5 fine pleomorphic microcalcifications grouped within a 6 mm region in the upper outer quadrant, mid-depth. No associated mass, no architectural distortion. Visible on both CC and MLO views as well as DBT. Not present on prior study 14 months ago — represents an interval finding warranting workup. Pleomorphic morphology with grouped distribution carries a non-trivial risk of ductal carcinoma in situ (DCIS) or early invasive disease [Lehman CD, Radiology 2017].
Right Breast — Other QuadrantsNormal
No mass or distortion identified in remaining quadrants. No skin or nipple retraction. Subareolar region unremarkable.
Left BreastNormal
No new finding. Stable scattered fibroglandular tissue. No mass, no distortion, no suspicious calcification.
AxillaeNormal
No abnormal lymphadenopathy on visualized portions of the axillae bilaterally.

BI-RADS Final Assessment & Differential

  • Ductal carcinoma in situ (DCIS)Moderate
    Grouped pleomorphic calcifications without mass are the most common DCIS presentation. Image-guided biopsy required for definitive diagnosis.
  • Atypical ductal hyperplasia (ADH) / atypical lobular lesionModerate
    High-risk lesions can present with similar calcifications; surgical excision often follows core biopsy diagnosis.
  • Benign fibrocystic change with calcificationsModerate
    Many BI-RADS 4B lesions are ultimately benign; biopsy resolves the diagnostic uncertainty.
  • Early invasive ductal carcinomaLow–Moderate
    Less likely without an associated mass, but possible — particularly with new pleomorphic calcifications.

Analytical Summary & Recommendations

Imaging impression

BI-RADS 4B — new grouped pleomorphic microcalcifications in the right upper outer quadrant. Diagnostic workup and tissue sampling are required.

Recommended next steps

  • Diagnostic mammogram with magnification views (CC and lateral) of the calcifications [ACR Practice Parameter 2023]
  • Stereotactic or DBT-guided core needle biopsy with clip placement for future localization
  • Multidisciplinary consultation (breast surgeon, radiologist, pathologist) once histology is available
  • Continue routine left-breast surveillance per institutional schedule
  • Discuss genetic risk evaluation if not already addressed (e.g., Tyrer-Cuzick / BRCA testing) given family history
⚠ Important
BI-RADS 4B is not a cancer diagnosis — it is a category that says "this is suspicious enough to require a biopsy." The biopsy is what answers the question. Do not delay the diagnostic workup; a 1–2 week timeline is reasonable. Most BI-RADS 4 lesions ultimately turn out to be benign, but the only way to know is to sample tissue.

Key Questions for Your Physician

  • Where will the biopsy take place, and how long until results are available?
  • Should I see a breast surgeon before or after the biopsy?
  • Given my mother's history, should I discuss genetic testing now?
  • If the biopsy result is high-risk but not cancer, what are the next steps?
  • What signs would warrant urgent contact (e.g., new lump, skin change, nipple change)?

What This Means for You

Your screening mammogram shows a small new finding in your right breast — a tiny group of calcium specks (called microcalcifications) that were not present 14 months ago. The mammogram report category is BI-RADS 4B, which means "suspicious enough to require a biopsy."

An important point: BI-RADS 4 is not a diagnosis of cancer. It is a way of telling your doctor that the finding needs further evaluation, because we cannot tell from images alone whether it is benign, a high-risk benign change, an in-situ change (DCIS), or, less commonly, an early cancer. The biopsy answers the question. Most BI-RADS 4 findings turn out to be benign.

The recommended next step is a diagnostic mammogram with magnification views, then a core needle biopsy guided by stereotactic imaging. This is typically a same-day, outpatient procedure with minimal recovery time. Results are usually available within a week.

Given your mother's history of breast cancer, this is also a good time to discuss genetic counseling and risk-assessment testing with your physician, regardless of the biopsy outcome.

Analysis Confidence 88%

High confidence in lesion identification, BI-RADS categorization, and management direction. Definitive characterization requires histopathology — the recommended biopsy is standard of care.

References

  1. Sickles EA, D'Orsi CJ, Bassett LW, et al. ACR BI-RADS Mammography. In: ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. American College of Radiology 2013.
  2. Lehman CD, Arao RF, Sprague BL, et al. National Performance Benchmarks for Modern Screening Digital Mammography. Radiology 2017;283(1):49–58.
  3. Monticciolo DL, Newell MS, Hendrick RE, et al. Breast cancer screening for average-risk women: ACR appropriateness criteria. J Am Coll Radiol 2017;14(9):1137–1143.
  4. Lee AY, Wisner DJ, Aminololama-Shakeri S, et al. Inter-reader variability in BI-RADS Atlas updates. Radiology 2017;285(2):428–35.
  5. NICE Guideline NG101: Early and locally advanced breast cancer: diagnosis and management. 2018 (updated 2024).